Dr. Carducci is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Summary
- Dr. Michael Carducci is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, and Sibley Memorial Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice 29 years. He specializes in hematologic oncology and is experienced in urologic oncology, and palliative medicine.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1992 - 1995
- University of ColoradoResidency, Internal Medicine, 1988 - 1992
- Wayne State University School of MedicineClass of 1988
Certifications & Licensure
- MD State Medical License 1992 - 2026
- VA State Medical License 2022 - 2026
- DC State Medical License 2012 - 2024
- CO State Medical License 1990 - 1993
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma Start of enrollment: 1997 Feb 01
- Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment Start of enrollment: 2000 Mar 01
- Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer Start of enrollment: 2002 Apr 25
- Join now to see all
Publications & Presentations
PubMed
- 605 citationsChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos Kyriakopoulos, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard
Journal of Clinical Oncology. 2018-01-31 - 73 citationsThe Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Matthew P. Deek, Kim Van der Eecken, Ryan Phillips, Neil R. Parikh, Pedro Isaacsson Velho
European Urology. 2021-01-05 - 655 citationsOutcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical TrialRyan Phillips, William Shi, Matthew P. Deek, Noura Radwan, Su Jin Lim
JAMA Oncology. 2020-05-01
Other
- Investigational approaches for the treatment of advanced prostate cancerCarducci MA, Antonarakis ES, Walczak JR, Pili R
http://www.uptodate.com/contents/investigational-approaches-for-the-treatment-of-advanced-prostate-c
UpToDate, Wolters Kluwer Health - 2013-04-10
Press Mentions
- Intervention to Improve Patient-Physician Communication May Improve Black Patient Participation in Clinical Trials, Study Led by Karmanos ResearcherFebruary 27th, 2023
- Dramatic Results Seen with Bone-Protecting Agents in Prostate Cancer PatientsJune 5th, 2019
- Trials Back Earlier Use of Androgen Receptor InhibitorsJune 3rd, 2019
- Join now to see all
Grant Support
- Phase I Clinical Trials Of New Anti-Cancer Targeted TherapiesNational Cancer Institute2008–2012
- DSMNational Cancer Institute2006–2010
- Phase I Clinical Trials Of New Anti-Cancer Targeted TherNational Cancer Institute2003–2007
- Foreign Accrual For U01ca70095 - 2006 Load.National Cancer Institute2006
- Restoration Of Gene Function In Prostate CancerNational Cancer Institute2003
- Phase I Trials Of Anticancer AgentsNational Cancer Institute2001–2002
- Phase I Trial Of Oral Phenylbutyrate In Solid TumorsNational Center For Research Resources2000–2002
- Dose/Pharmacokinetics Of ABT 627 In AdenocarcinomaNational Center For Research Resources2000–2002
- Multiple Dose Study Of Safety Of ABT 627National Center For Research Resources1998–2002
- A Randomized Controlled Phase II Clinical Trial Of ModulDivision Of Cancer Prevention And Control1999–2000
- Phenylbutyrate Bioactivity Assessment In Prostate CancerNational Cancer Institute1997–2000
- Gene Therapy For Prostate CancerNational Cancer Institute1996–2000
- Continuous Infusion Phenylbutyrate Given For 120 HRS Every 21 DaysNational Center For Research Resources1997
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/michael-carducci
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: